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ABSTRACT 
 
OBJECTIVES: Many symptoms associated with concussion are also associated with 
symptoms related the menstrual cycle, for example headache, nausea, and fatigue. This 
study sought to investigate the relationship between these symptoms at different points in 
the menstrual cycle to determine if it is appropriate to compare baseline symptom reports 
obtained in one menstrual phase with post-concussive symptom reports from another.  
METHODS: 17 female and 11 male participants recruited from the psychology 
participant pool were given a measure of post-concussive symptoms (PCSS) and a 
measure of mood and stress symptoms (DASS). Females were also given a menstrual 
symptom questionnaire (DSRS). Participants completed the questionnaires on two 
occasions, two weeks apart. Females completed the questionnaires once during the 
follicular phase of their menstrual cycle and once during the luteal phase.  
RESULTS: No significant differences between female and male reports on the PCSS or 
DASS were found. Symptoms on the DASS were found to decrease over time. PCSS and 
DSRS scores in females were significantly correlated at both time points, but more 
strongly correlated during the luteal phase. PCSS scores over time were correlated in 
male but not female participants.  
CONCLUSIONS: The absence of significant results indicating an increase in the number 
and severity of symptoms experienced by females during the luteal phase suggests that 
there may be no need to control for menstrual phase at baseline. However, given that 
female PCSS scores were not correlated between times 1 and 2, type of symptoms may 
vary even if overall number and severity do not. 
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CHAPTER 1 
 
RELEVANCE AND IMPORTANCE 
 
Mild traumatic brain injuries (mTBI) have been identified as an important health 
problem deserving of more attention in order to prevent the incidence of new injuries 
(Upshur & Echlin, 2014). In the context of sports injuries, mTBIs are commonly referred 
to as concussions and generally represent mTBIs of mild severity. The incidence of 
sports-related concussion is estimated to be between 1.6 and 3.8 million annually in the 
United States (Langlois, Rutland-Brown & Wald, 2006). It is usually defined as trauma to 
the head resulting in a Glasgow Coma Scale score of 13-15, less than 24 hours of post-
traumatic amnesia, and no evidence of intracranial abnormality on CT scan (Tellier et al., 
2009). Individuals who sustain mTBI often report a constellation of symptoms, which can 
include symptoms such as headache, nausea, fatigue, irritability, sleep disturbance, mood 
swings, and anxiety, among others (King, 1997; McCrea et al., 2003; Ryan & Warden, 
2003; Wiebe, Comstock & Nance, 2011). Although not severe in nature, these symptoms 
can interfere with the daily lives of those who experience them. In addition, there is 
evidence that sustaining multiple mTBIs may predispose individuals to developing a 
myriad of other serious health problems, including early-onset dementia, substance-use 
disorders, and other mental illness, which further illustrates the importance of researching 
the effects of mTBI in order to prevent new incidences (Canadian Institutes of Health 
Research, 2012). Although the vast majority of individuals who sustain a mTBI will 
recover within weeks to months (Frommer et al., 2006; Guskiewicz et al., 2003; McCrea 
et al., 2003), there is an increased risk of prolonged symptoms and for long-term 
consequences on health as well as on cognitive and emotional functioning after sustaining 
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a mTBI (Frommer et al., 2006; Guskiewicz et al., 2003; Meehan, Mannix, Stracciolini, 
Elbin, & Collins, 2013). Further, the odds of suffering prolonged symptoms after a mTBI 
are increased in those who report more symptoms after injury compared with those who 
report an average number of symptoms (Meehan et al., 2013). 
Sex Differences in mTBI 
There have been differences observed between male and female athletes after 
incurring mTBIs. The rates of injury of mTBI in female athletes is higher compared to 
male athletes (Covassin, Swanik & Sachs, 2003). In addition, females have been shown 
to suffer from more adverse effects after mTBI than males, including being cognitively 
impaired approximately 1.7 times more frequently (Broshek, Kaushik, Freeman, 
Erlanger, Webbe, & Barth, 2003), as well as experiencing more severe and prolonged 
symptoms (King, 2014). The reason that females experience higher rates of and worse 
outcome after mTBI is unclear, but there are multiple potential contributors. For example, 
females are smaller in size and generally have weaker neck muscles then men (Covassin, 
Swanik & Sachs, 2003). There is also evidence that the influence of the female sex 
hormones, particularly estrogen and progesterone, play a role in somatic, affective, and 
cognitive symptoms reported (King, 2014). For example, estrogen is related to migraines 
and anxiety and progesterone is involved with maintaining regular sleep patterns and 
learning novel information (Andersen, Bittencourt, Antunes & Tufik, 2006; MacGregor, 
Frith, Ellis, Aspinall & Hackshaw, 2006; Seeman, 1997). 
Despite noted sex differences after mTBI there have been many contradictory 
findings as to whether or not females and males differ at baseline in terms of symptoms 
and neuropsychological ability (Covassin, Schatz & Swanik, 2007; Mihalik, Ondrak, 
MENSTRUAL PHASE & PCS SYMPTOM REPORTING 3 
 
 
Guskiewicz & McMurray, 2009; Valovich McLeod, Bay, Lam & Chhabra, 2012). The 
Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test is a 
commonly used baseline symptom and cognition measure. The manual indicates that 
there are slight gender differences in the normative data for the various subtests, which 
include verbal memory, visual memory, visual motor speed and reaction time (ImPACT 
Application, Inc., 2011). The manual also presents means and standard deviations for the 
Post-Concussion Symptom Scale (described in more detail below), which show slight but 
statistically insignificant differences between males and females at different ages 
(ImPACT Application, Inc., 2011). Covassin et al. (2007) also found no significant 
difference between the sexes on any composite scores on the ImPACT or Total symptom 
score. Another study found that female athletes endorse significantly more symptoms 
with mild severity at baseline than males (Covassin, Swanik, Sachs, Kendrick, Schatz, 
Zillmer & Kaminaris, 2006). To further complicate things, Frommer et al. (2011) found 
that after concussion, females report more neurobehavioural and somatic symptoms (i.e., 
drowsiness and sensitivity to noise) and that males report more cognitive symptoms (i.e., 
amnesia, confusion/disorientation). Frommer et al. go on to recommend that symptoms 
experienced after potential head injuries reported by females, even though the 
presentation may be different from the presentation that has been typically seen in males, 
should be linked to the possibility of incurring a concussion rather than assuming some 
other neuropsychological cause (2011).  
One potential confound in this research may be the fluctuating hormonal changes 
in females associated with their menstrual cycles. It is widely known that females of 
reproductive age experience hormonal fluctuations over the course of approximately 28 
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days in relation to their menstrual cycles. Menstrual cycle symptoms are experienced by 
20-40% of women and many of the same symptoms that are present in post-concussive 
syndrome are also associated with menstrual cycle phase (Archer, 2006). Despite the high 
incidence of menstrual cycle symptoms experienced by women, research investigating 
the effect of menstrual cycle phase on baseline concussion symptom reporting is limited.  
The Menstrual Cycle and Hormonal Influences 
There is strong evidence to support the claim that the female sex hormones 
estrogen and progesterone influence mood and mental function, including many of the 
symptoms that are assessed during athlete baseline assessments, such as difficulty 
concentrating, irritability, and headache, to name a few (Farage, Osborn & MacLean, 
2008). Hormonal fluctuations over the menstrual cycle are suggested to modulate 
emotion and cognition through dopaminergic transmission (Sacher et al., 2013).  There is 
evidence that varying concentrations of female sex hormones, estrogen and progesterone 
in particular, over the course of different menstrual cycle phases influence a number of 
brain structures including the striatum, hippocampus, thalamus, hypothalamus, insula, 
amygdala, frontal cortex (specifically, the inferior and middle frontal gyri), anterior 
cingulate cortex, and parietal areas that may all play a role in the presence of mood and 
cognitive symptoms (Hines, 2010; Sacher, Okon-Singer & Villringer, 2013; Fanselow & 
Dong, 2010; Steiner, 2003; Toffoletto, Lanzenberger, Gingnell, Sundström-Poromaa & 
Comasco, 2014).  
The varying concentrations of female sex hormones influence the presence of 
symptoms differently over the course of the month (Sacher et al., 2013). The menstrual 
cycle is divided into phases: the follicular phase, ovulation, and the luteal phase. The 
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follicular and luteal phases consist of varying concentrations of the female sex hormones, 
including estrogen and progesterone, which can be seen in Figure 1 (Terner & De Wit, 
2006; Sacher et al., 2013). The follicular phase refers to the time between the onset of 
menses and ovulation and the luteal phase refers to the period between ovulation and the 
onset of menses (Sacher et al., 2013). The menstrual cycle typically lasts about 28 days; 
day 1 refers to the onset of menses, which lasts approximately until day 7, and the 
premenstrual period lasts between days 22 and 28 (Fraser, 1985).  There is evidence that 
eumenorrheic females (those who are experiencing normal or regular menstrual cycles 
and who are not taking any hormone-influencing medications) experience different brain 
activation patterns between the follicular and luteal phases than those females who are 
not eumenhorrheic (Toffoletto et al., 2014). 
Progesterone concentrations are very low during menses and the early part of the 
follicular phase, then rise after ovulation, peaking mid-luteal phase, and falling rapidly 
before menses (Terner & De Wit, 2006; Sacher et al., 2013). Estrogen concentrations are 
also low during menses and the early part of the follicular phase, rise in the middle and 
late follicular phase with a peak around ovulation, remain moderate during the luteal 
phase, and decrease sharply before the onset of menses (Terner & De Wit, 2006). Most 
studies analysing changes related to the menstrual cycle compare performance during the 
late follicular phase (when progesterone concentrations are low and estrogen 
concentrations are high) with the late luteal phase (when progesterone concentrations are 
high and estrogen concentrations are low; Sacher et al., 2013).  
Neurocognitive tasks for which women have been shown to perform better than 
men, such as verbal memory, are most clearly differentiated between the sexes when 
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females’ estrogen concentrations are higher: during the luteal phase (Warren, Gurvich, 
Worsley & Kulkarni, 2014). Conversely, high progesterone concentrations have been 
observed to have negative effects on neurocognitive performance (Warren et al., 2014).  
 
Figure 1. Hormonal fluctuations over the menstrual cycle. This Wikipedia and 
Wikimedia Commons image is from the user Chris 73 and is freely available at 
http://commons.wikimedia.org/wiki/Image:MenstrualCycle.png under the creative 
commons cc-by-sa 2.5 license. 
 
MENSTRUAL PHASE & PCS SYMPTOM REPORTING 7 
 
 
Estrogen. The presence of female sex hormones, estrogen in particular, is 
associated with a number of somatic and affective symptoms. For example, falling 
concentrations of estrogen after a period of sustained estrogen presence is associated with 
migraines (MacGregor et al., 2006). Sixty percent of women who experience migraines 
link them to their menstrual cycle, but only about 8 to 14% of these are actually related to 
menstrual cycle phase (Case & Reid, 1998). Estrogen has also been shown to up-regulate 
GABA receptors, which implicates it with increasing levels of anxiety and depression 
(Seeman, 1997). The presence of estrogen itself has not been found to directly dampen 
mood, but the cyclical nature of estrogen presence in the brain and the resulting on-and-
off nature of the binding of estrogen receptors has been suggested to make women more 
vulnerable to stress (Seeman, 1997). It is speculated that the recurrent withdrawal of 
estrogen may interfere with the ability to neutralize the effects of glucocorticoids released 
during periods of stress (Seeman, 1997). 
Progesterone. The effects of progesterone have been less studied than those of 
estrogen. It is involved in a number of processes throughout the body, including normal 
sleep, mood, appetite, learning, and memory (Andersen et al, 2006). 
Follicle-Stimulating Hormone and Luteinizing Hormone. These hormones are 
produced by the pituitary gland. Follicle-stimulating hormone causes secretions of 
estrogen by stimulating the growth of follicles in the ovaries, and both work to cause 
ovulation and the release of estrogen and progesterone (Bowen, 2004). 
Overall, the influence of fluctuating sex hormones in women is known to 
influence many brain regions, resulting in changes to cognitive and affective processing 
over the course of the menstrual cycle, including levels of anxiety, depression, and 
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somatic complaints (Sacher et al., 2013; Seeman, 1997; Toffoletto et al., 2014). However, 
there are inconsistent findings about the nature and existence of specific mood changes 
between menstrual cycle phases in the literature (Romans, Clarkson, Einstein, Petrovic & 
Stewart, 2012). Some of these changes, which take place near the end of the menstrual 
cycle, are often referred to as premenstrual syndrome (PMS). There is no one universally 
agreed upon definition of PMS and it affects women differently. As such the various 
studies of symptoms may focus on different aspects associated the syndrome. There are 
over 60 instruments used to measure various symptoms related to the menstrual cycle, 
and many only focus on increases in the negative symptoms (e.g. irritability) rather than 
including information about positive symptoms (e.g. happiness) that may fluctuate over 
the course of the menstrual cycle (Romans et al., 2012). One study of experimentally 
naïve women found increases of anxiety, irritability, depression, and tension but lower 
reports of fatigue, confusion, sleep problems, and depression in the premenstrual phase 
(Parlee, 1982). Another study found that 70% of women complained of irritability, 
decreased morale, depression, and fatigue premenstrually (Paulson, 1961). Choi and 
McKeown’s study of PMS symptoms revealed than many women subjectively 
acknowledge the experience of some symptoms, but do not believe that their symptom 
presentations are severe enough to be considered full-blown cases of PMS (1997).  
Related to there being no one universally agreed upon definition, studies have 
also studied the presence of symptoms at slightly different time points within the 
menstrual cycle. Some research has indicated that the symptoms associated with PMS do 
not end as soon as menstruation occurs, but rather linger for two or three days (Romans et 
al., 2012).  
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Hormones and mTBI 
The relationship between menstrual phase and outcome following mTBI is 
unclear. However, it has been observed that during their childbearing years females are 
more likely to report greater symptoms after incurring mTBI than males, suggesting the 
possibility that estrogen or progesterone production disruption may influence the 
presence of symptoms (Bazarian, Blyth, Mookerjee & McDermott, 2010). In fact, injury 
to the anterior pituitary gland may result in the disruption of endogenous estrogen and/or 
progesterone production, resulting in withdrawal of those hormones (Bazarian et al., 
2010). High concentrations of progesterone have been linked with a reduction of neural 
impairment after mTBI whereas the findings on estrogen’s influence have been mixed 
(Broshek et al., 2005).  
Lastly, there are potentially confounding factors to consider when examining the 
role of menstrual cycle phase on symptom reporting in athletes, such as use of oral 
contraceptives and level of physical activity. These factors have been shown to influence 
menstrual cycle related symptomatology, as well as general symptom reporting and 
mood, and will be discussed next.  
Oral Contraceptive Use 
The use of oral contraceptives is an important consideration for research on the 
effects of sex hormones in women. A Canadian study found that 43% of women of 
reproductive age use oral contraceptives (Black, Yang, Wu Wen, Lalonde, Guilbert, & 
Fisher, 2009). Oral contraceptives prevent pregnancy by influencing the hypothalamic-
pituitary-ovarian axis and are the most common medication prescribed to women of 
reproductive age (Archer, 2006). They have been found to reduce the symptoms 
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associated with menses, such as migraines, fatigue, and depression (Yonkers, O’Brien & 
Eriksson, 2008). Eumenorrheic females have been shown to endorse a higher number of 
symptoms and report an increased symptom severity score compared to females using 
oral contraceptive pills on baseline concussion testing (Mihalik, 2009). As the use of oral 
contraceptives reduces symptoms in women who use them, it is important to determine 
whether women are using them when research evaluating symptom prevalence and/or 
severity is being conducted.  
Physical Activity 
Physical activity has been shown to reduce the number and severity of general 
symptoms reported (Choi & Salmon, 1995) as well as PMS symptoms (Scully, Kremer, 
Meade, Graham & Dudgeon, 1998). Further, symptoms associated with menstruation 
have been shown to be reduced with the implementation of an exercise-training program 
(Koushkie Jahromi, Gaeini & Rahimi, 2008). Physical fitness levels have also been 
shown to influence the number of symptoms experienced, with higher levels of physical 
fitness being associated with fewer reported symptoms (Mrazik, Naidu, Lebrun, Game & 
Matthews-White, 2013). In particular, physical activity has been linked with a reduction 
in depression intensity (Nabkasorn, 2005). Therefore, it is important to consider that level 
of physical fitness may influence the number and severity of symptoms endorsed by an 
individual. 
The Current Study 
In sports-related concussion management programs, athletes are often assessed 
pre-season in order to establish a baseline level of cognitive performance as well as a 
baseline level of symptom reporting. It is important to consider symptoms at baseline in 
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order to assess whether or not the individual is ready to re-engage in physical activity, 
such as playing in a sporting event, after incurring a mTBI. Engaging in physical activity 
before the brain has had sufficient time to heal after injury can result in more severe post-
concussive symptoms and a longer recovery period (Kissick & Johnston, 2005). In order 
to ensure that female athletes are ready to re-engage in physical activity without incurring 
further insult to their brains it is important to understand the relationship between the 
presence of symptoms at baseline and how they may vary over the course of the 
menstrual cycle. 
The motivation for this study comes from the fact that many symptoms of PCS 
and PMS overlap. This study will examine how the symptoms experienced by women 
during different phases of the menstrual cycle overlap and relate to the symptoms 
typically associated with incurring a concussion by examining symptom prevalence over 
different stages of the menstrual cycle. It is important to understand the non-concussion 
related causes of these symptoms in athletes in order to help us better understand which 
symptoms are due to concussion versus other sources after a head injury is incurred. This 
study seeks to determine how appropriate it is to compare baseline symptom reports with 
post-concussive symptom reports of female athletes during different menstrual phases. 
Hypotheses 
1. It was hypothesized that the number and severity of symptoms reported on a post-
concussion symptom report commonly used for baseline assessments would 
correlate highly with the number and severity of symptoms reported on a measure 
of menstrual symptoms in females in the follicular phase and again in the luteal 
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phase of their menstrual cycles, due to the overlapping nature of many of the 
symptoms experienced in both conditions.  
2. It was hypothesized that women will experience fewer and less severe affective 
and somatic symptoms at their first testing session, which occurred during the 
follicular phase, and more affective and somatic symptoms during the second 
testing session, which occurred in the luteal phase, as concentrations of both 
estrogen and progesterone are increased compared with menstrual phase and 
symptoms typically decline at the onset of menstruation (Backstrom et al., 1983). 
Further, it is hypothesized that the number and severity of symptoms reported by 
males will remain constant at both measurement points.  
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CHAPTER 2 
DESIGN AND METHODOLOGY 
Participants 
Participants for this study were recruited from the psychology participant pool at 
the University of Windsor. The participant pool is composed of undergraduate students 
who elect to take part in psychological research in exchange for extra credit in eligible 
courses. A total of 44 participants (31 female) were recruited. Despite the advertisement 
for the study saying that only women who have experienced a regular menstrual cycle 
(lasting approximately 28 days, for at least the past two months) may participate, four 
female participants reported irregular menstrual cycles and thus were eliminated from the 
analyses. Five women were deleted from analysis as they reported on the questionnaires 
being in a different place in their menstrual cycle than what they told the experimenter. 
Two females were fasting for Ramadan at the time of their second session (one of which 
was already eliminated for reporting an irregular cycle), and were eliminated from 
analyses due to the potential confounding effects of fasting on the symptom reports. One 
additional female had to be deleted due to an administration error resulting in her 
menstrual cycle data never being collected. Due to the fact that this was a repeated 
measures study, significantly more participants than were needed for analysis were 
sought for recruitment in an attempt to account for attrition and potential noise or 
invalidity in the data collected. Nonetheless, fewer than the desired number of 
participants signed up for the study. Three female participants and two male participants 
had to be eliminated from the analysis due to attrition. Thus, a total of 17 female and 11 
male participants were included in analyses.  
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Participants received reminder emails for the study by the participant pool system 
the night before their appointments. Participants were incentivised with the awarding of 
half of a bonus point each time they spent half an hour completing the surveys, which 
they were able to use toward their final grade on any eligible course, as per the 
participant pool regulations.  
 The risks of participating in this study were minimal and fully explained to 
participants in the consent form. Questions about mood were collected as part of this 
study, and sometimes discussing the presence of mood symptoms can draw attention to 
them, resulting in psychological distress, so the questionnaires were followed with a page 
that included information for accessing community mental health resources for all 
participants.  
Measures 
Demographics. Participants were asked to record their age, gender, and level of 
education completed. This information was used for descriptive purposes and was 
collected using Fluid Surveys. Female participants were also asked to confirm that they 
have regular cycles and to record the date that their last menstrual period commenced in 
order to ensure that they began the study at approximately the same place in their 
menstrual cycle, approximately 5-7 days after the onset of their last period.  
Post-Concussion Symptom Scale. The Post-Concussive Symptom Scale (PCSS; 
ImPACT Application Inc., 2011) questionnaire was used to evaluate the presence of 
some typical symptoms associated with post-concussive syndrome, such as headache, 
fatigue, drowsiness, and difficulty concentrating (see Appendix A for the symptom list). 
The PCSS is a self-report measure which uses a 7-point Likert scale ranging from “0 - not 
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experiencing” to “6 - severe” to rate the presence of 22 symptoms. Participants are asked 
to rate the severity of each symptom as they are currently experiencing it. A Total 
symptom score can also be calculated though combining the report of the all symptoms 
measured. A series of psychometric analyses demonstrated that Immediate Post-
Concussion Assessment Testing (ImPACT®) Test, from which the PCSS is taken, has 
adequate concurrent, divergent, and convergent validity for clinical inferences of post-
concussion outcome in amateur athletes (ImPACT Application Inc., 2007). Adequate 
internal consistency of the PCSS has been reported (α = 0.88 to 0.94) (McLeod & Leach, 
2012). The meaningful change score has been reported to be 6.8 points, indicating that a 
difference of approximately 7 points on the PCSS Total score at the second instance of 
responding to the questionnaire suggests that there is a significant difference in the 
number of symptoms that the person is experiencing (McLeod & Leach, 2012). Test-
retest reliability has also been shown to be adequate (r = 0.8) (ImPACT Application Inc., 
2011). 
Depression Anxiety Stress Scales. The severity of depressive, anxiety, and stress 
symptoms was evaluated using the Depression Anxiety Stress Scales (DASS; Lovibond 
& Lovibond, 1995). The DASS questionnaire can be found in Appendix B. The DASS is 
a self-report measure that consists of 42 questions answered on a Likert scale, which 
ranges from “0 – did not apply to me at all” to “3 – applied to me very much, or most of 
the time”. Thus higher scores correspond with more severe symptoms. Participants are 
asked to rate how much the statement applied to them over the past week. After 
completion by the participants, the scale is divided into Depression, Anxiety, and Stress 
composite scores. The Depression scale evaluates the presence of symptoms typically 
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associated with depression, including hopelessness, anhedonia, self-depreciation, and 
dysphoria. Sample items from the Depression scale include statements like “I felt that I 
had lost interest in just about everything” and “I felt I wasn't worth much as a person”. 
The Anxiety scale assesses situational anxiety and autonomic arousal. Sample items from 
the Anxiety scale include “I was aware of the action of my heart in the absence of 
physical exertion (e.g., sense of heart rate increase, heart missing a beat)” and “I was 
worried about situations in which I might panic and make a fool of myself ”. The Stress 
scale assesses levels of chronic, non-specific levels of arousal, including becoming easily 
agitated, difficulty relaxing, and irritability. Sample items from the Stress scale include “I 
found it hard to wind down” and “I tend to overreact to situations”. The DASS has a 
reputation for distinguishing anxiety, depression, and stress well and has adequate 
internal consistency and concurrent validity, with Cronbach's alphas for the Depression, 
Anxiety, and Stress subscales shown to be .97, .92, and .95, respectively (Antony, 
Bieling, Cox, Enns & Swinson, 1998).  Internal consistency and temporal stability of the 
measure has been found to be adequate in clinically depressed samples (Page, Hooke & 
Morrison, 2007). The DASS has been used in clinical research of TBI and is described as 
a useful tool for measuring emotional status following an acquired brain injury (Dahm, 
Wong & Ponsford, 2013; Ownsworth, Little, Turner, Hawkes & Shum, 2008). 
Physical Activity Scale. The Physical Activity Scale (PAS; Aadahl & Jørgensen, 
2003) was used to assess participants’ levels of physical activity during the previous 
week. The PAS was translated to English from a Danish version of the scale and has been 
shown to exhibit adequate face and concurrent validity (Aadahl & Jørgensen, 2003). It 
was selected due to its ease of administration. The scale can be found in Appendix C. To 
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complete the PAS, participants are asked to estimate the amount of time they spend on an 
average day engaging in tasks of nine different intensity levels. These nine different 
levels range from tasks involving very low energy expenditure, i.e. “sleep, rest”, to high 
levels of energy expenditure, i.e. “running, racing on bicycle, playing soccer, handball, 
or tennis”. The nine levels are associated with different levels of metabolic equivalents 
(MET) which estimate energy expenditure based on intensity of activity (Aadahl & 
Jørgensen, 2003). For each activity level measured, the MET value is multiplied by time 
spent on that activity, which are then added together to represent physical activity level 
on an average day (Aadahl & Jørgensen, 2003). 
Daily Symptom Rating Scale. Female participants recorded the presence and 
severity of common menstrual symptoms through rating the severity of their experience 
of a series of symptoms at each testing session. The symptoms were measured using the 
Daily Symptom Rating Scale (DSRS; Taylor, 1979), which can be found in Appendix D. 
The DSRS measures 17 symptoms typically associated with changes over the menstrual 
cycle and can be divided into somatic and affective indices. Symptoms were rated on a 5-
point Likert scale to measure the severity of the symptoms which ranges from “0 = not at 
all” to “5 = a very large amount”. The DSRS was constructed from questions used on 
other menstrual symptom questionnaires and has been shown to exhibit adequate test-
retest reliability, with all coefficients above 0.8 (Haywood, Slade & King, 2002). 
Criterion validity was also assessed through correlational analysis of four criteria: 
whether the woman had ever consulted a doctor for her symptoms, the number of tablets 
taken in premenstrual week, self-rating of symptom severity and estimation of severity in 
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relation to most women, which all significantly correlated with the DSRS Total, 
Affective, and Somatic scores (Haywood, Slade & King, 2002).  
Menstrual Phase. Women were instructed to attend their first testing session 
approximately 5-7 days after the onset of their last menstrual cycle. This testing session 
took place during participants’ follicular phase. The women then returned 14 days later 
for their second testing session, when they were expected to be in the midst of their luteal 
phase, when progesterone concentrations are high and estrogen concentrations are lower.  
Procedure  
Participants signed up for the study through the participant pool at the University 
of Windsor. Females and males signed up for separate studies on the participant pool so 
that the researcher had the ability to cap the number of females and/or males if the 
desired number of participants were reached. The research was conducted in person in 
Dr. Abeare’s laboratory. The consent form, demographic questions, and questionnaires 
were presented online using Fluid Surveys. Informed consent was first obtained from all 
participants. Following their consent, all participants entered demographic information, 
including age, gender, and level of education. Females were also asked to disclose the 
date of the onset of their last menstrual period in order to confirm that they were 
commencing the study at the desired time during their menstrual cycle, as well as confirm 
that they have experienced a regular cycle (lasting 21 to 35 days for at least the past three 
months, as suggested by the Mayo Foundation for Medical Education and Research, 
2016). Females were also asked do disclose if they currently use any form of hormonal 
contraception. Participants then completed the PAS, PCSS, and DASS questionnaires, the 
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order of which was randomized for each participant. Females also filled out the DSRS, 
which was presented in a randomized order among the other questionnaires.  
The sessions took approximately twenty minutes to complete. Each participant 
was asked to complete the battery again at the same time of day two weeks later. 
Participants were emailed by the participant pool to remind them of their second 
appointment. They were awarded half of a bonus point each time they completed the 
surveys that went towards their final grade in any eligible course, as per the participant 
pool regulations. Female participants were asked to complete the first survey 
approximately 5-7 days after the onset of their last menstrual cycle and male participants 
were allowed to begin participation on any day they chose, as they do not have the same 
monthly fluctuations in hormones that females do.  
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CHAPTER 3 
DATA ANALYSES AND RESULTS 
Screening and analyses of the data were conducted using IBM SPSS Statistics 
Version 22. Data cleaning was completed by removing participants who did not fit the 
inclusion criteria.  Finally, assumptions of statistical tests were assessed, including 
Shapiro-Wilk test, and kurtosis and skewness values for normality, and Levene’s test for 
homogeneity of variance. Correlational analyses were conducted to examine the 
relationship of the PCSS and DSRS over time in the female participants. A series of 2 
(time) x 2 (sex) mixed factorial ANOVAs were conducted using the various measures in 
order to test differences in symptom reports in both sexes over time.  
Power 
An a priori power analysis was conducted using the program G*Power, a free 
program that allows a priori power estimates to be conducted, to determine the required 
sample size for analysis. A power of .80, alpha value of .05, and effect size of 0.3859 
were specified for the power analysis. The effect size of 0.3859 was estimated based on 
the findings of Gallant, Hamilton, Popiel, Morokoff and Chakraborty (1991) with respect 
to the effects of menstrual cycle phase on daily mood and symptoms. A sample size 18 
participants of each gender was indicated. Unfortunately, this sample size was not 
attained and thus many of the analyses conducted had insufficient power.  
Data Screening 
Before any further analyses were conducted, data was assessed for missingness. 
There were no instances of missing data on the DSRS or DASS questionnaires. One 
female participant was given the wrong Fluid Surveys link, and thus demographic 
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information related to her menstrual phase was never collected. This participant was 
deleted from analyses as her menstrual phase and regularity could not be verified. One 
male participant did not complete the PCSS correctly at time 1 and thus his scores were 
not included in analyses that involved the PCSS.  
The PAS data was examined, and it was found that most of the participants did 
not accurately rate the number of hours they spent doing the different levels of activity, as 
many of their responses did not add up to 24 hours. As such, the amount of time spent 
doing various activity levels and their MET equivalents were calculated, and then that 
score was prorated to account for 24 hours to yield the PAS Total score. 
Visual inspection of box plots indicated that there were potential outliers on some 
of the questionnaires. Z scores were calculated for each questionnaire at each time point. 
There was one participant with a Z score of 3.10 on PCSS Total score at time 1, another 
participant with a DASS Anxiety Z score of 2.98 at time 2 and one other participant with 
a DASS Stress Z score of 2.73 at time 2. All other Z scores on all questionnaires or 
subscales were within 2.5 standard deviations of the means. It was decided to not remove 
these potential outliers as the sample size was already small, and also because these 
participants may represent variability in the population that is meaningful.   
Two of the items on the PCSS and the DSRS are the exact same symptom. 
Correlational analyses of these items were evaluated between the two time points as a 
measure of validity. The item “headache” was positively correlated at the p < 0.01 level 
on both measures, at both time points (r = 0.876 and r = 0.845 at time 1 and 2, 
respectively). The item “irritability” was positively correlated at the p < 0.01 level on 
both measures at time 2 (r = 0.845), but it was not significantly correlated between the 
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measures at time 1 (r = 0.188). This suggests that there may be some inconsistencies in 
the data at time 1 threatening the validity, so findings should be interpreted with caution.  
Assumptions 
Originally, the use of a repeated measures multivariate analysis of covariance 
(MANCOVA) was planned. However, due to the small sample size and resulting lack of 
power, the covariance pieces of the analyses were not conducted. Thus, the assumptions 
of a mixed factorial analysis of variance (ANOVA) were tested, which include normality, 
independence of observations, and homogeneity of variance. 
To investigate normality of the data, Shapiro-Wilk tests, visual inspection of 
scatterplots, and through examination of skewness and kurtosis cut-offs (absolute values 
of 2 and 3, respectively) were conducted. In the overall sample, the DASS depression 
subscale at time 2 was kurtotic (value = 2.47). In analysis of the females only, DASS 
Anxiety at time 2 was kurtotic (value = 2.36). Analysis of the male participants revealed 
kurtotic data on the PCSS at both time 1 and 2 (values of 4.84 and 3.42, respectively). 
Shapiro-Wilks analyses also revealed significant values in the overall sample for the 
DASS depression subscale at time 1, DASS Anxiety subscale at times 1 and 2, and DASS 
Stress subscale and time 2 (p’s < 0.05). Analysis of the females only revealed significant 
values for the same variables as the overall sample, as well as DSRS Total at time 2 and 
Somatic subscale at time 2 (p’s < 0.05). In the males only PCSS Total at time 1 and 2, 
and DASS depression subscale were also significant (p’s < 0.05). These results suggest 
that the assumption of normality was violated.  
Homogeneity of variance was confirmed through values on Levene’s test being 
insignificant. It is also suggested that the highest variance value not be more than four 
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times the lowest variance. For the males, the highest variance value was 569.9 on the 
PCSS Total at time 1 and the lowest was only 8.2 on the DASS Anxiety subscale. In 
females, the highest variance was 294.1on the PCSS at time 2 and the lowest was 14.4 on 
the DASS Depression subscale at time 2. Thus, there was more variance than ideal in the 
data.  
Independence of observations was assumed for the sex variable, as individuals in 
the male and female groups were all collected from different participants. No one person 
participated more than once. As this was a repeated measures design, the second 
independent variable represented time, and the same participants did participate in both 
instances. Repeated measures designs have the assumption of homogeneity of covariance, 
but seeing as this study only analyzed two different points in time this assumption is not 
relevant, as there are not multiple variances between more than three time points.  
ANOVA is known to be robust to violations if only one of the assumptions of 
normality or homogeneity of variance, but in this instance both assumptions may be 
violated. Ideally a non-parametric test would be used instead of ANOVA, however, non-
parametric tests require larger power to show significant results. As the small sample size 
in the current study limits the power of any analyses, it was decided to use ANOVA 
rather than non-parametric tests.  
Demographic and Descriptive Data 
Descriptive statistics for demographic variables of the sample are summarized in 
Table 1 below. Age and education were not found to be significantly different between 
the male and female groups. Correlational analysis was used to determine whether a 
relationship existed for age or education with PCSS or DASS scores. Age positively 
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correlated with PCSS at time 2 (r = 0.42, p < 0.05) and level of education was negatively 
correlated with the DASS Depression subscale at time 1 (r = -0.55, p > 0.01). Due to the 
fact that only one dependent variable was correlated with age and one with education it 
was deemed unnecessary to use age and education as covariates. Further, the small 
sample size would not have allowed for analysis of covariates. Due to the restricted 
ranges of age, education, and scores on the measures administered, these correlations are 
likely not meaningful.  
Table 1 
 
Demographic Data Means and Standard Deviations 
 Age Years of Post-Secondary School Completed 
Whole Sample  
(N=28) 
22.50 
(4.08) 
2.43 
(1.43) 
Males 
(N=11; 39.29%) 
23.00 
(4.67) 
2.18 
(1.47) 
Females 
(N=17; 60.71%) 
22.18 
(3.76) 
2.59 
(1.42) 
 
Birth Control Usage. A series of mixed factorial analyses of variance 
(ANOVAs) were also run using oral contraceptive use as a between subjects variable and 
time as a within subjects variable to determine if there was a significant difference in the 
between the women who use oral contraceptives, those who do not, and males on 
symptom reports. The dependent variables examined included the PCSS, DASS 
Depression subscale, DASS Anxiety subscale, and DASS Stress subscale. The analysis of 
the PCSS resulted in no main effect of time [F(1, 24) = 3.45, p = 0.08], oral contraceptive 
use [F(2, 24) = 0.52, p = 0.60], or their interaction [F(2, 24) = 0.14, p = 0.87]. Similarly, 
there were no significant effects on the DASS Depression subscale for time [F(1, 25) = 
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3.45, p = 0.08], oral contraceptive use [F(2, 25) = 0.52, p = 0.60], or their interaction 
[F(2, 25) = 0.14, p = 0.87]. The DASS Anxiety subscale showed significant effects for 
time [F(1, 25) = 5.63, p = 0.03], but not for oral contraceptive use [F(2, 25) = 0.17, p = 
0.85] or the interaction [F(2, 25) = 0.77, p = 0.48]. The DASS Stress subscale also 
indicated significant differences on time [F(1, 25) = 5.20, p = 0.03], but not contraceptive 
use [F(2, 25) = 0.34, p = 0.71] or the interaction [F(2, 25) = 0.63, p = 0.54]. 
Mixed factorial ANOVAs were also conducted on the female participants using 
oral contraceptive use as an independent variable, along with time, and using menstrual 
symptoms as the dependent variable. Firstly, the DSRS Total was used, revealing no 
significant effects of time [F(1, 15) = 3.62, p = 0.08], oral contraceptive use [F(1, 15) = 
0.27, p = 0.61] or the interaction [F(2, 15) = 0.98, p = 0.34]. The DSRS Affective 
subscale was also examined, again revealing no significant effects of time [F(1, 15) = 
1.17, p = 0.30], oral contraceptive use [F(1, 15) = 0.15, p = 0.70] or the interaction [F(2, 
15) = 0.04, p = 0.84]. Lastly, the DSRS Somatic subscale revealed no significant effects 
of time [F(1, 15) = 3.92, p = 0.07], oral contraceptive use [F(1, 15) = 0.30, p = 0.60] or 
the interaction [F(2, 15) = 1.57, p = 0.23]. Thus, oral contraceptive use did not 
significantly differentiate women on the PCSS or DSRS, or on the DASS Anxiety, DASS 
Depression, or DASS Stress subscales. 
Physical Activity. The PAS was included with the intent to use its total score as a 
measure of physical activity. It was planned to be used as a covariate in the main analysis 
surrounding the second hypothesis, which stated that women would experience more and 
more severe PCS symptoms during their luteal phase compared with their follicular phase 
and compared with men. This was believed to be due to the fact that exercise is known to 
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decrease the presence of mood and other PCS symptoms (Byrne & Byrne, 1993; Leddy et 
al., 2010). Due to the small sample size in the study, which limits statistical power, and 
also due to the inconsistently correct responses on the PAS, the physical activity scale 
was not used as a covariate.  
 The PAS scores were examined to see whether they correlated with DASS 
subscales, PCSS Total, or DSRS Total or subscales at the same point in time. The PAS 
did not significantly correlate with any of the other measures at the same time point. 
However, PAS scores at time 1 did correlate significantly with PAS scores at time 2 (r = 
0.78, p < 0.01), demonstrating adequate test-retest reliability. 
Menstrual and Post-Concussive Symptom Correlations  
Correlational analyses were also conducted between the PCSS and DSRS at each 
time point for female participants in order to examine the influence that menstrual related 
symptoms have on PCSS symptom reporting. At time 1 the DSRS Total and both 
subscales were all positively correlated with PCSS Total score (DSRS Total score r = 
0.58, DSRS Somatic subscale r = 0.51, and DSRS Affective subscale r = 0.49, p’s < 
0.05). At time 2 the DSRS Total and both subscales were also all positively correlated 
with PCSS Total score (DSRS Total score r = 0.88, DSRS Somatic subscale r = 0.94, and 
DSRS Affective subscale r = 0.61, p’s < 0.01). Thus the hypothesis that these two 
measures would be correlated was supported. PCSS and DSRS scores were also more 
highly correlated at time 2, when it was predicted that symptom reports on these 
questionnaires would be higher.  
 Follow-up analyses revealed that the correlation between the PCSS at time 1 and 
time 2 in the female participants was only 0.26, which was not significant at the p < 0.05 
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level. The DSRS Total was significantly correlated between times 1 and 2 (r = 0.57, p < 
0.05). The Affective subscale was significantly correlated between the two times (r = 
0.70, p < 0.01) but the Somatic subscale was not (r = 0.43, p = 0.09).  
Effects of Time/Menstrual Phase and Sex on Symptom Reports  
The second hypothesis was tested, which predicted that women would experience 
more symptoms with greater severity during the luteal phase of their menstrual cycle 
compared with during their follicular phase, and compared with what men experienced 
over two different time points. Table 2 shows the means and standard deviations of 
scores on the measures administered. 
Table 2 
 
Means and Standard Deviations of Measures Administered 
  Females Males 
PAS 1 43.27 
(7.27) 
47.00 
(7.55) 
PAS 2 42.73 
(10.36) 
50.74 
(10.32) 
DASS Depression 1  5.18 
(5.25) 
6.73 
(6.29) 
DASS Depression 2 4.35 
(3.79) 
3.55 
(4.37) 
DASS Anxiety 1 6.00 
(5.90) 
7.09 
(5.65) 
DASS Anxiety 2 3.71 
(4.27) 
4.18 
(2.86) 
DASS Stress 1 13.76 
(11.35) 
11.82 
(8.22) 
DASS Stress 2 9.88 
(8.65) 
7.18 
(6.18) 
PCSS 1 28.00 
(15.20) 
23.80 
(23.87) 
PCSS 2 22.82 
(17.15) 
16.45 
(17.03) 
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A series of mixed factorial ANOVAs were conducted in order to examine the 
effects of sex over time on symptom reporting, thus the independent variables were sex 
and time. The dependent variables included anxiety, depression, and stress from the 
DASS and the PCSS Total symptom score, which were all analyzed in separate tests. A 
series of univariate ANOVAs were conducted rather than a multivariate analysis of 
variance due to the small sample size and resulting lack of power for the analysis. 
Although the implementation of non-parametric statistics may have been better suited to 
this data, there was simply not enough power for any significant results to appear. Due to 
the small sample size and resulting power, as well as the unequal groups, the results of 
the following analyses should be considered exploratory and be interpreted with caution. 
PCSS. The first mixed factorial ANOVA was conducted on PCSS scores. Neither 
the main effect of time nor of sex was significant [F(1, 25) = 4.00, p = 0.06 and F(1, 25) 
= 0.90, p = 0.35, respectively]. Nor was there a significant interaction of sex by time 
[F(1, 25) = 0.26, p = 0.62]. The observed power was 0.49 for time, 0.15 for sex, and 0.08 
for the interaction effect. Box’s M test, which is used to analyze homogeneity of 
variance-covariance matrices, was not significant (7.79, p = 0.71). This suggests that, 
despite the hypothesis that females would have higher reports of symptoms on the PCSS, 
both sexes typically report stable numbers of symptoms over time when no injury is 
incurred. 
It was also observed that the PCSS scores in females at time 1 did not significantly 
correlate with PCSS scores at time 2 (r = 0.26). Conversely, PCSS scores of male 
participants were significantly correlated at time 1 and time 2 (r = 0.87). Given that the 
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test has been shown to have adequate test-retest reliability (r = 0.8) it is of note that the 
females’ scores were not significantly correlated (ImPACT Application Inc., 2011).  
DASS Depression. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted 
on DASS Depression scores. There was a main effect of time [F(1, 26) = 4.46, p = 0.04], 
but there was no main effect of sex [F(1, 26) = 0.05, p = 0.82]. The interaction of sex and 
time was also not significant [F(1, 26) = 1.55, p = 0.23]. A visual representation of the 
results can be seen in Figure 2 below. The observed power was 0.53 for time, 0.06 for 
sex, and 0.22 for the interaction effect. Box’s M test was not significant (2.15, p = 0.58). 
This suggests that contrary to the hypothesis, females did not report more symptoms of 
depression at time 2 than males did.  Rather, both sexes reported a decline in symptoms 
of depression over time.  
 
Figure 2. DASS Depression by sex and time 
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DASS Anxiety. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted on 
the DASS Anxiety subscale. There was a main effect of time [F(1, 26) = 6.12, p = 0.02], 
but there was no main effect of sex [F(1, 26) = 0.25, p = 0.62]. The interaction of sex and 
time was also not significant [F(1, 26) = 0.09, p = 0.77]. A visual representation of the 
results can be seen in Figure 3 below. The observed power was 0.66 for time, 0.08 for 
sex, and 0.06 for the interaction effect. Box’s M test was not significant (2.17, p = 0.58). 
This suggests that, again, contrary to the hypothesis, females did not report more 
symptoms of anxiety at time 2 than males did.  Rather, both sexes reported a decline in 
symptoms of depression over time. 
 
Figure 3. DASS Anxiety by sex and time 
 
DASS Stress. A 2 (time) x 2 (sex) mixed factorial ANOVA was conducted on the 
DASS Stress subscale. There was a main effect of time [F(1, 26) = 5.58, p = 0.03], but no 
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main effect of sex [F(1, 26) = 0.59, p = 0.45]. The interaction of sex and time was also 
not significant [F(1, 26) = 0.04, p = 0.84]. A visual representation of the results can be 
seen in Figure 4 below. The observed power was 0.62 for time, 0.12 for sex, and 0.06 for 
the interaction effect. Box’s M test was not significant (2.70, p = 0.48). Once again, the 
finding that females did not report more symptoms of stress at time 2 than males did was 
contrary to the hypothesis.  Both sexes reported a decline in symptoms of stress over 
time. 
 
Figure 4. DASS Stress by sex and time 
 
 DSRS. A series of paired t-tests were also conducted in the female participants to 
determine if there was a significant effect of time on the DSRS Total score and subscales. 
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None of the t-tests yielded significant differences between times 1 and 2 (Total: t = 1.97, 
p = 0.07; Affective: t = 1.13, p = 0.28; Somatic: t = 2.02, p = 0.06). The DSRS Total was 
significantly correlated with itself between times 1 and 2 (r = 0.57, p = 0.02). The 
Affective subscale was also significantly correlated with itself between times 1 and 2 (r = 
0.70, p < 0.01). The Somatic subscale was not significantly correlated between times 1 
and 2 (r = 0.43, p = 0.09). DSRS Total, Affective, and Somatic subscale means and 
standard deviations can be seen in Table 3. 
Table 3 
 
DSRS Means and Standard Deviations Over Time 
 Time 1 Time 2 
Total 26.82 
(13.29) 
21.18 
(12.30) 
Affective subscale 15.24 
(7.18) 
13.82 
(5.29) 
Somatic Subscale 11.59 
(8.09) 
7.35 
(8.06) 
 
Differences in Female PCSS Scores 
Difference scores between times 1 and 2 on each item of the PCSS were 
calculated for the women in order to examine which symptoms in particular were 
decreasing over time. The top five symptoms that decreased at time 2 from reports at time 
1, which all decreased 10 or more points overall, in descending order were “irritability”, 
“feeling more emotional”, “sadness”, “drowsiness”, and “sleeping more than usual”. 
However, only “irritability” was significantly different at time 2 (t = 2.67, p = 0.02) and 
the rest of the symptoms had p values above the 95th percent confidence interval 
(remaining p’s = 0.23, 0.10, 0.19, 0.28, respectively). The only symptoms that actually 
increased at time 2 were, in order of largest increase to smallest, “numbness or tingling”, 
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“difficulty remembering”, and then “feeling like ‘in a fog’ ” and “nervous/anxious”. 
None of these increases were significant (p’s = 0.56, 0.67, 0.89, 0.86, respectively). No 
other PCSS symptoms were statistically significantly different between the time points.  
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CHAPTER 4 
DISCUSSION 
 This study examined the relationships between reports of symptoms commonly 
associated with the menstrual cycle, and also those associated with incurring a 
concussion, over time. There were three main hypotheses that were explored and each 
will be discussed below.  
PCS and Menstrual Symptom Correlations 
The first hypothesis was that the number and severity of PCS symptoms reported 
would correlate at each point in time with the number and severity of menstrual 
symptoms reported in women. This hypothesis was investigated by examining the 
correlations between the PCSS Total score, DSRS Total score, DSRS Somatic subscale, 
and DSRS Affective subscale scores. At time 1 the PCSS Total correlated significantly 
with all three DSRS scores, therefore the hypothesis was supported at time 1. At time 2, 
the PCSS Total significantly correlated with all three DSRS scores. Thus, the hypothesis 
was also supported at time 2. It is interesting to note that PCSS and DSRS scores were 
more significantly correlated at time 2 (r = .58 at time 1 vs. r = .88 at time 2), when it 
was predicted that symptom reports on these questionnaires would be higher due to the 
increasing concentrations of female sex hormones. Fisher’s Z-transformation was 
calculated, revealing a z score of 1.89, p = 0.03 for a one-tailed test. A one-tailed test was 
used due to the prediction that symptom reports on these questionnaires would be higher 
due to the increasing concentrations of female sex hormones. Perhaps there is some effect 
of menstrual phase, or the underlying sex hormones, that resulted in stronger correlations. 
Effect of Menstrual Phase  
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It was hypothesized that women would experience fewer and less severe affective 
and somatic symptoms during their first testing session, occurring during the follicular 
phase, and more affective and somatic symptoms during the second testing session, 
which occurred in the luteal phase, as concentrations of both estrogen and progesterone 
are increased compared with during the follicular phase, and symptoms typically decline 
at the onset of menstruation (Backstrom et al., 1983). It was also hypothesized that male 
symptom reports would remain constant over time, thus resulting in an interaction effect. 
This hypothesis was not supported given that all of the symptom reports decreased at the 
second testing session, although not all of the decreases were statistically significant. 
Further, the interactions between the time points and genders on the participants’ scores 
on the PCSS, the DASS Depression, the DASS Anxiety, and the DASS Stress subscales 
were not significant. This finding was not expected, but has the positive implication that 
use and comparison of these measures in females at various points in the menstrual cycle 
may be appropriate should these results be replicated with a larger and more 
representative sample. However, the observed power for these analyses related to sex 
were low, 0.15, 0.06, 0.08, and 0.12 for the PCSS, DASS Depression, DASS Anxiety, 
and DASS Stress subscales, respectively. With stronger power a potential main effect of 
sex may emerge. Relatedly, the observed power for the analyses related to the interaction 
of sex and time point were also quite low. On the PCSS power was 0.08, on the DASS 
Depression subscale it was 0.22, on the DASS Anxiety subscale it was 0.06, and on the 
DASS Stress subscale it was 0.06. Again, with stronger power there may emerge an 
interaction effect. 
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Reasons for these unexpected results may be partially explained by a number of 
factors. Having the male sample included in the study was helpful for interpreting these 
results because males do not experience a similar monthly cycle to females. As the males 
also showed a similar decrease in the number and severity of symptoms they reported, it 
suggests that the decreases in symptoms over time were not due to changes in sex 
hormones, but rather some other factor. Further, participants were tested at the same time 
of day, so daily hormonal fluctuations can be ruled out as culprits for changing levels of 
symptoms. In addition, participant data was collected over three semesters (winter, 
interim, and summer), thus time of academic year, and corresponding life stressors, 
should not have been a confounding factor in this study. Although, perhaps simply being 
further along in a semester influences students’ affect and symptom presentation, as the 
second part of the assessment always occurred two weeks after the first.  
Despite the fact that many of the symptoms measured are associated with 
hormonal changes over the course of the menstrual cycle, it is also possible that this study 
did not measure symptoms at the most opportune times to pick up differences. Female 
participants completed part one of the study about five to seven days after the onset of 
their last menstrual period, and the second part of the study was thus completed about day 
19 to 21 of their cycles. Many of the symptoms measured may be more likely to increase 
in severity later in the luteal phase (i.e. when “premenstrual syndrome” occurs) then 
when measurement took place. Most symptoms thought to occur as part of the 
“premenstrual syndrome” only occur in the days leading up to the onset of menstruation, 
and potentially in the first 2-3 days of menstruation (Romans et al., 2012). It may have 
been better to have participants come back a few days later for their second assessment, 
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but due to differing schedules on different days of the week, it was thought that it would 
facilitate participation in the study better if appointments took place of the same day of 
the week, as it was desired to have participants return at the same time of day, due to 
daily fluctuations in hormones. It was further desired to keep the day of the week 
constant in case of any effects of the day of week on symptoms, in case, for example, 
participants were more fatigued later in the week due to attending early classes or work 
schedules.  
Despite the lack of significant interaction between time and gender on PCSS 
symptoms, there are potential clinical implications. If this finding is replicable with a 
larger sample size, it suggests that it is appropriate to compare baseline symptom reports 
of females obtained in one menstrual phase with post-concussive symptom reports from a 
different menstrual phase without concern for elevations in number and severity of 
symptoms due to the menstrual cycle. That said, the different symptoms were only 
examined at the item level in a cursory way in this study. It is possible that the particular 
symptoms or types of symptoms reported may differ over time, which may be related to 
menstrual phase.  
Relatedly, it was observed that scores on the PCSS in males were significantly 
correlated between time 1 and time 2 (r = 0.87) but we not significantly correlated for 
females (r = 0.26). While the number and severity of symptoms in the overall female 
sample was found not to significantly differ between time points, their scores at time 2 
were not related to their scores at time 1, whereas male scores were similar to each other. 
This suggests that perhaps there is some effect of female sex hormones on the presence of 
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different symptoms at different points in the menstrual cycle rather than simply 
influencing the overall number and severity of symptoms.  
Oral Contraceptive Use  
Given the statistical limitations due to the small sample size, it is not surprising 
that no group differences were observed between women who do and no not use oral 
contraceptives (eumenorrheic women = 9 and oral contraceptive users = 8). As oral 
contraceptive pills are commonly prescribed to help decrease the symptoms of 
menstruation, the use of these pills may mask the individuals who would otherwise 
experience more different and more severe menstrual symptoms. However, we were 
unable to observe any possible effects due to limitations on statistical power related to the 
small sample sizes. 
Limitations and Future Direction of Research 
There are a number of limitations to the current study, the first and most evident 
being the small sample size included in the analyses. As a result of this small sample size, 
many of the analyses were under-powered. Conducting a similar study with an adequate 
number of participants may yield different results. In addition, the sample's demographics 
were determined through the participant pool sign up process. The results of this study 
may not be generalizable to non-university students, or people who did not fall into the 
age range of those who participated.  
This study also sought to use physical activity as a covariate in analyses. Physical 
activity has been shown to affect the presence of the symptoms measured on the PCSS 
(Malleck, Richardson, Considine & Abeare, Manuscript in preparation). Due to the 
inconsistent reporting on the PAS, the integrity of this variable was not ideal. Participants 
MENSTRUAL PHASE & PCS SYMPTOM REPORTING 39 
 
 
were likely more accurate at rating certain levels of activity rather than others. For 
example, the estimate for the number of hours they slept will likely be more accurate than 
the number of hours spent “standing, washing dishes or cooking, driving a car or truck” 
because the latter activities are often completed for shorter amounts of time and more 
often, making them more difficult to estimate than activities completes during one longer 
period of time, such as sleeping. PAS scores were calculated based on the percent of 
hours reported on the questionnaire, so the scores may have underestimated the total level 
of activity by participants due to underreporting of various activities while awake. Future 
research should further investigate the use of physical activity as a covariate with a larger 
sample size and more accurately measured.  
When data was collected for this study the titles of the questionnaires were 
included due to copyright restrictions. It is unknown if participant responding was 
influenced by these titles. For example, it is possible that participants may have 
underrated symptoms on the PCSS due to the fact that they saw the word “concussion” 
and had not recently incurred a concussion and thus did report the presence of symptoms 
on this questionnaire. In future research it is advisable to remove any such titles so as to 
remove the possibility of biasing participant responding.  
Another limitation of this study was that hormone concentrations were estimated, 
not directly measured. Future research could use salivary or core temperature 
measurements to get more accurate appraisals of menstrual phase.  
Further, this study measured just two time points during the menstrual cycle. 
These time points were chosen as estrogen and progesterone were at different 
concentrations, but hormones vary continuously over the cycle, which may indicate 
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different concentrations of symptomatology that were not picked up on in this study. One 
particular time point of interest may be ovulation, after which estrogen concentrations 
rapidly fall. This study was not able to precisely isolate the time of ovulation due to lack 
of availability of direct measures of hormone concentrations. It would also be interesting 
to measure symptomatology later in the luteal phase, when “premenstrual syndrome” is 
thought to occur.  
Relatedly, the same menstrual phase (follicular) was consistently measured first, 
as it was believed it would be easier to facilitate participant sign-up requesting first 
sessions take place 5-7 days after the onset of participants’ last menstrual period rather 
than some longer period, or asking them to come in a certain number of days before their 
next menstrual period as they may not have known exactly when it would occur. It was 
feared that longer time intervals between a noticeable event (i.e. onset of menses) would 
introduce more variability regarding when during their menstrual cycles the females 
participated. Ideally, phase during the menstrual cycle when measurements took place 
would have also been counterbalanced to reduce any bias related to test-retest effects.  
Finally, as mentioned above, this study looked simply at the number of symptoms 
endorsed at two different time points in the menstrual cycle rather than examining in 
detail which symptoms in particular, or types of symptoms (e.g. somatic, cognitive), that 
were endorsed at each time point. This would be of particular interest given the finding 
that female scores on the PCSS were not statistically significantly correlated between the 
time points, but the male scores were. Future research could examine the specific 
symptoms individually to determine if there is a difference in the particular types 
symptoms that are reported at different times over the menstrual cycle.  
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CHAPTER 5 
CONCLUSIONS 
This study represents an effort toward elucidating the contributing factors of 
menstrual phase and female sex hormones toward baseline and post-concussive 
neuropsychological symptoms. The results of this study indicated that female and male 
symptom reports were similar at different time points in the females’ menstrual cycles in 
terms of number and severity of symptoms. The implication of these findings is that it 
does appear to be appropriate to compare female baseline symptom reports obtained in 
one menstrual phase to post-concussive symptom reports obtained from a different 
menstrual phase without concern that the number and severity of symptoms are due to 
variance in female sex hormones rather than due to the effects of the incurred mTBI. 
With that said, many analyses lacked power and there were also some preliminary 
indications that the type of symptoms experienced by women may vary over the course of 
the menstrual cycle. More detailed examination of types of symptoms experienced over 
the menstrual cycle is warranted. 
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APPENDIX A 
The Post-Concussion Symptom Scale (PCSS) 
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Instructions Given for the PCSS 
 
Please complete the paper questionnaire you were given at this time. Please indicate the 
level for which you are CURRENTLY experiencing the symptoms listed, as per the scale 
on the paper. So, you should only fill out one column with your ratings for today. Do not 
worry about writing the date or calculating the total. When you are finished please return 
to this page and click next.  
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APPENDIX B 
DEPRESSION ANXIETY STRESS SCALES (DASS) 
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Depression Anxiety Stress Scales 
Source: 
Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states: 
Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression 
and Anxiety Inventories. Behaviour Research and Therapy, Vol 33(3), 335-343. doi: 
10.1016/0005-7967(94)00075-U, © 1995 by Elsevier. Reproduced by Permission of 
Elsevier.  
Permissions: 
Test content may be reproduced and used for non-commercial research and educational 
purposes without seeking written permission. Distribution must be controlled, meaning 
only to the participants engaged in the research or enrolled in the educational activity. 
Any other type of reproduction or distribution of test content is not authorized without 
written permission from the author and publisher. Always include a credit line that 
contains the source citation and copyright owner when writing about or using any test.  
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APPENDIX C 
PHYSICAL ACTIVITY SCALE (PAS) 
 
How physically active are you on an average weekday?  
 
In the physical activity scale you see some examples of different levels of physical activity. Try to assess 
how much time you spend on each level on an average weekday. Start with level A and continue 
downward.  
 
If you normally sleep 7 hours, you should mark the 7-h box of level A. If you watch TV for an hour and a 
half, you should mark the 30-min box and the 1-h box of level B. If you are not active on all activity levels, 
you should leave levels unmarked.  
 
Please note that the total number of minutes and hours should amount to 24 􏱋 an average weekday and 
night. You may find the column on the right helpful when adding the minutes and hours together  
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APPENDIX D 
DAILY SYMPTOM RATING SCALE (DSRS) 
Please record your experience during this day of the feelings and sensations listed below. 
 
Daily Questions 
 0 
not at all 
1 
very little 
2 
little 
3 
moderate 
amount 
4 
large 
amount 
5 
very large 
amount 
1) Hopelessness       
2) Depression       
3) Lack of initiative       
4) Withdrawal       
5) Tension       
6) Irritability       
7) Argumentativeness       
8) Cheerfulness       
9) Outgoingness       
10) Energy       
11) Breast swelling or 
tenderness 
      
12) Abdominal swelling       
13) Swelling of face, hands, 
ankles 
      
14) Pelvic or abdominal 
pain 
      
15) Backache       
16) Headache       
17) Tiredness       
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